Huadong Medicine's Units Get NMPA's Nod for Obesity Drug Clinical Trials

MT Newswires Live10-11

Huadong Medicine (SHE:000963) said its units, Hangzhou Zhongmei Huadong Pharmaceutical, and Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong, received approval from China's National Medical Products Administration (NMPA) to conduct clinical trials for their semaglutide injection for weight management, according to a Friday filing with the Shenzhen bourse.

Semaglutide is a weight loss treatment for overweight or obese individuals. Iy may also be used as a type-II diabetes.

The pharmaceutical share prices were down by 3% at Friday's closing.

Price (RMB): Â¥33.22, Change: Â¥-1.1, Percent Change: -3.32%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474572520?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-11 16:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474572520","market":"fut","top_or_hot":-1,"title":"Huadong Medicine's Units Get NMPA's Nod for Obesity Drug Clinical Trials","media":"MT Newswires Live","content":"<html><body><p> Huadong Medicine (SHE:000963) said its units, Hangzhou Zhongmei Huadong Pharmaceutical, and Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong, received approval from China's National Medical Products Administration (NMPA) to conduct clinical trials for their semaglutide injection for weight management, according to a Friday filing with the Shenzhen bourse.</p><p>Semaglutide is a weight loss treatment for overweight or obese individuals. Iy may also be used as a type-II diabetes.</p><p>The pharmaceutical share prices were down by 3% at Friday's closing.</p><p>Price (RMB): Â¥33.22, Change: Â¥-1.1, Percent Change: -3.32%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huadong Medicine's Units Get NMPA's Nod for Obesity Drug Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuadong Medicine's Units Get NMPA's Nod for Obesity Drug Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-11 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Huadong Medicine (SHE:000963) said its units, Hangzhou Zhongmei Huadong Pharmaceutical, and Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong, received approval from China's National Medical Products...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2474572520","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474572520","pubTimestamp":1728636833,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Huadong Medicine  said its units, Hangzhou Zhongmei Huadong Pharmaceutical, and Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong, received approval from China's National Medical Products Administration  to conduct clinical trials for their semaglutide injection for weight management, according to a Friday filing with the Shenzhen bourse.Semaglutide is a weight loss treatment for overweight or obese individuals. Iy may also be used as a type-II diabetes.The pharmaceutical share prices were down by 3% at Friday's closing.Price : 33.22, Change: -1.1, Percent Change: -3.32%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0196":"行业龙头","000963":"华东医药","BK0175":"白马股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0132":"高送转概念","BK0188":"融资融券","BK0183":"MSCI概念","BK0209":"零售","BK0187":"一线龙头","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC"},"translate_title":"华东医药旗下单位肥胖药物临床试验获NMPA认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000963":0.9},"content_text":"Huadong Medicine (SHE:000963) said its units, Hangzhou Zhongmei Huadong Pharmaceutical, and Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong, received approval from China's National Medical Products Administration (NMPA) to conduct clinical trials for their semaglutide injection for weight management, according to a Friday filing with the Shenzhen bourse.Semaglutide is a weight loss treatment for overweight or obese individuals. Iy may also be used as a type-II diabetes.The pharmaceutical share prices were down by 3% at Friday's closing.Price (RMB): Â¥33.22, Change: Â¥-1.1, Percent Change: -3.32%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474572520"}